Business
AlzeCure Pharma to present at Redeye Investor Forum on June 11
STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...
About this update from Alzecure Pharma Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company will participate at Redeye Investor Forum Stockholm on June 11 at 14:35 CET, where CEO Martin Jönsson will give a company presentation and answer questions about the latest developments and Alzecure's future plans.","length":528,"tagName":"p"},{"type":"text","content":"Watch the livestream via https://www.redeye.se/events/1102502/investor-forum-stockholm","length":86,"tagName":"p"},{"type":"text","content":"The session will also be available after the event on AlzeCure's company page at Redeye www.redeye.se/company/alzecure-pharma , and on AlzeCure's website www.alzecurepharma.se/en/presentations-and-interviews/ .","length":218,"tagName":"p"},{"type":"text","content":"Time & date: 14:35 CET, June 11, 2025Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden","length":98,"tagName":"p"},{"type":"text","content":"For more information, please contact","length":36,"tagName":"p"},{"type":"text","content":"Martin Jönsson, CEOTel: +46 707 86 94 [email protected]","length":75,"tagName":"p"},{"type":"text","content":"About AlzeCure Pharma AB (publ)","length":31,"tagName":"p"},{"type":"text","content":"AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless.","length":489,"tagName":"p"},{"type":"text","content":"NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifyin...